Breaking news

In this paper, the authors systematically analysed lung tissue samples from 38 patients who died from COVID-19 in two hospitals in northern Italy between Feb 29 and March 24 2020.

In this paper, just published in Lancet, the authors performed a dose-escalation, single-centre, open-label, non-randomised, phase 1 trial of a recombinant adenovirus type-5 (Ad5) vectored COVID-19 vaccine in Wuhan, China.

In this paper, the authors investigated the effects of physical distance, face masks, and eye protection on virus transmission in healthcare and non-healthcare settings.

In this paper just published in the New England Journal of Medicine, the authors report the natural history of asymptomatic SARS-CoV-2 infection from part of the cohort of the 410 infected people on the cruise ship, Diamond Princess, who were asymptomatic at the time of testing.

In this paper, the authors conducted a prospective national-level data collection of patients treated with mechanical thrombectomy (MT), across 45 days of pandemic containment measures, compared to patients treated during the same calendar period in 2019.

On June 3, we published in the Breaking News section of this site the article entitled “Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis” previously published in Lancet. On June 13, the article was retracted by three of the four authors.

In this case series, the authors systematically assessed the presence of deep vein thrombosis among patients with severe COVID-19 in an intensive care unit (ICU) in France. They prospectively performed a venous ultrasonogram of the legs in all patients on admission to ICU and repeated the test after 48 hours if the first examination was normal. All patients received standard anticoagulant prophylaxis at hospital admission.

In this paper, recently published in Lancet, the authors report the findings of autopsies of six patients (four men and two women, aged 58–82 years) who died from COVID-19 in April 2020 in Munich, Germany. The period from onset of symptoms to admission ranged from 2–10 days.

In this open-label, multicentre, randomised clinical trial, recently published in JAMA, the authors evaluate the efficacy and adverse effects of convalescent plasma therapy for patients with COVID-19.

This review, recently published in JAMA Neurology, serves to summarise available information regarding coronaviruses in the nervous system, identifies potential tissue targets and routes of entry of SARS-CoV-2 into the central nervous system, describes the range of clinical neurological complications that have been reported thus far in COVID-19, and their potential pathogenesis.

One of the immediate and ongoing neurological challenges posed by the COVID-19 pandemic is the management of patients who are undergoing immunotherapy for existing neuroimmunological disease.

Transcranial pulse stimulation (NPS), a new ultrasound based brain stimulation technique, is reported in this comprehensive original article. Beisteiner et al. describe the technical details as well as a clinical study on 35 patients with Alzheimers disease. NPS showed overall improvement lasting up to three month.

In this paper recently published in Nature Medicine, Leung et al. aimed to explore the importance of respiratory droplet and aerosol routes of transmission with a particular focus on coronaviruses, influenza viruses and rhinoviruses.

In this paper recently published in Annals of Neurology, Pilotto et al., described the case of a 60-year old subject with SARS-CoV-2 infection but only mild respiratory abnormalities who developed akinetic mutism due to encephalitis.

In this paper recently published in Epilepsia, Aledo-Serrano et al. evaluated the impact of the pandemic on patients with genetic, developmental and epileptic encephalopathies (DEEs) and their caregivers in Spain.